Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing changes in their interests in the company's Ordinary shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director share allocations and does not contain financial performance data.
Material Changes
On December 31, 2012, Non-Executive Directors were provisionally allocated awards over Ordinary Shares and ADSs through the annual reinvestment of dividends paid throughout 2012. These allocations were informed to the Company and Directors on January 2, 2013.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing details the automatic reinvestment of 2012 dividends into share awards for Non-Executive Directors.
- Allocations were made in both Ordinary Shares (average price £13.43) and ADSs (average price $43.39).
- Specific allocations were recorded for directors including Sir Christopher Gent, Prof Sir Roy Anderson, Dr Stephanie Burns, Ms Stacey Cartwright, Sir Crispin Davis, Ms Judy Lewent, Sir Deryck Maughan, Dr Daniel Podolsky, Mr Tom de Swaan, and Sir Robert Wilson.
- No financial performance metrics or strategic outlook are included in this specific report.